Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient cerebral organoids capture Alzheimer's disease proteomic biomarkers and drug targets.

bioRxiv : the preprint server for biology·2026
Same author

Evaluating the causal effect of mitochondrial dysfunction on Alzheimer's disease and Parkinson's disease using polygenic risk scores and Mendelian randomization.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

An aging hallmark, Alzheimer's disease, and <i>APOE</i> nexus.

Journal of Alzheimer's disease : JAD·2026
Same author

Limbic-predominant neuroimaging correlates of plasma p-Tau217 in preclinical and clinical Alzheimer's disease.

Frontiers in aging neuroscience·2026
Same author

Downward bias in the association between APOE and Alzheimer's disease using prevalent and by-proxy disease sampling in the All of Us research program.

BMC medical genomics·2026
Same author

Structural signature of plasma proteins classifies the status of Alzheimer's disease.

Nature aging·2026

Related Experiment Video

Updated: Jul 9, 2026

Histological Examination of Mitochondrial Morphology in a Parkinson's Disease Model
06:07

Histological Examination of Mitochondrial Morphology in a Parkinson's Disease Model

Published on: June 23, 2023

Complex I deficiency in Parkinson's disease frontal cortex.

W Davis Parker1, Janice K Parks, Russell H Swerdlow

  • 1Department of Neurology, University of Virginia School of Medicine, Charlottesville, Virginia 22908, USA. dp8m@virginia.edu

Brain Research
|December 7, 2007
PubMed
Summary

Parkinson's disease (PD) involves complex I deficiency beyond the substantia nigra. Methodological factors are crucial for detecting this mitochondrial dysfunction in PD frontal cortex.

Related Experiment Videos

Last Updated: Jul 9, 2026

Histological Examination of Mitochondrial Morphology in a Parkinson's Disease Model
06:07

Histological Examination of Mitochondrial Morphology in a Parkinson's Disease Model

Published on: June 23, 2023

Area of Science:

  • Neuroscience
  • Biochemistry
  • Mitochondrial Biology

Background:

  • Parkinson's disease (PD) is often associated with complex I (NADH:ubiquinone oxidoreductase) deficiency.
  • Previous studies localized this complex I loss primarily to the substantia nigra in PD brains.

Purpose of the Study:

  • To investigate the paradox of complex I activity loss in Parkinson's disease (PD) brain.
  • To determine if complex I deficiency extends beyond the substantia nigra in PD.

Main Methods:

  • Assessed activity of mitochondrial electron transport chain complexes (I-IV) in frontal cortex from PD and aged control brains.
  • Utilized various assay conditions and tissue preparations, including purified mitochondria.
  • Evaluated the effect of bovine serum albumin on enzyme activity and discrimination.

Main Results:

  • Demonstrated increasingly significant losses of complex I activity in PD frontal cortex with increasing mitochondrial purity.
  • Found no significant differences in activities of complexes II, III, and IV between PD and control frontal cortex.
  • Observed that bovine serum albumin enhanced activity but reduced discrimination between PD and controls.

Conclusions:

  • Complex I deficiency in Parkinson's disease (PD) brain is not restricted to the substantia nigra.
  • Methodological considerations, particularly tissue preparation and assay conditions, are critical for accurately demonstrating complex I loss in PD.